文献速递流行病学与生物统计基础与转化研究

慢性阻塞性肺疾病的多维诊断方法

A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease.
PubMed 文献 · JAMA · 2025-01-01

这项队列研究纳入COPDGene(9416名成人)和CanCOLD(1341名成人)两个纵向队列,评估一种整合呼吸症状与CT影像异常的多维COPD诊断方案。该方案将部分无气流阻塞者新诊断为COPD,这些个体全因死亡、呼吸相关死亡、急性加重风险更高且FEV1下降更快;部分有气流阻塞者不再被归类为COPD。

要点

  • 新诊断方案整合气流阻塞、CT肺气肿或支气管壁增厚、呼吸困难、呼吸生活质量差和慢性支气管炎。
  • 无气流阻塞但符合次要诊断标准者新诊断为COPD后,全因死亡风险升高(校正HR 1.98)。
  • 新诊断COPD者呼吸相关死亡风险升高(校正HR 3.58)、急性加重增多(校正IRR 2.09)、FEV1下降更快。

核心结论

  • 整合呼吸症状、呼吸生活质量、肺量计检查和CT结构异常的新COPD诊断方案可将部分个体新归类为COPD,这些个体全因死亡、呼吸相关死亡、急性加重和肺功能下降风险更高;部分有气流阻塞但无呼吸症状或结构肺病证据者不再被归类为COPD。

研究设计与样本

  • 队列研究,纳入COPDGene队列10305名参与者(2007年11月9日至2011年4月15日入组,随访至2022年8月31日)和CanCOLD队列1561名参与者(2009年11月26日至2015年7月15日入组,随访至2023年12月31日)。
  • 暴露为新多维COPD诊断方案:主要诊断类别为存在主要标准(支气管舒张后FEV1/FVC比值<0.70)且至少1项次要标准;次要诊断类别为至少3项次要标准(呼吸症状可能由其他原因所致者必须包括肺气肿和支气管壁增厚)。

主要发现

  • COPDGene中9416名成人(入组时平均年龄59.6岁,标准差9.0;5035名男性,占53.5%;3071名黑人,占32.6%;6345名白人,占67.4%;4943名目前吸烟,占52.5%),5250名无气流阻塞者中811名(15.4%)经次要诊断类别新诊断为COPD,4166名有气流阻塞者中282名(6.8%)被归类为无COPD。
  • 新诊断为COPD者与归类为无COPD者相比,全因死亡校正风险比1.98(95%CI 1.67-2.35;P<.001),呼吸相关死亡校正风险比3.58(95%CI 1.56-8.20;P=.003),急性加重校正发生率比2.09(95%CI 1.79-2.44;P<.001),FEV1年下降校正β=-7.7 mL/年(95%CI -13.2至-2.3;P=.006)。
  • 肺量计有气流阻塞者中,按新诊断方案不再归类为COPD者的结局与无气流阻塞者相似。
  • CanCOLD中1341名成人,新归类为COPD者急性加重更多(校正发生率比2.09;95%CI 1.25-3.51;P<.001)。

关键数值与推荐

  • 主要诊断类别:支气管舒张后FEV1/FVC比值<0.70且至少1项次要标准(CT肺气肿或支气管壁增厚、呼吸困难、呼吸生活质量差、慢性支气管炎)。
  • 次要诊断类别:至少3项次要标准,呼吸症状可能由其他原因所致者必须包括肺气肿和支气管壁增厚。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Individuals at risk for chronic obstructive pulmonary disease (COPD) but without spirometric airflow obstruction can have respiratory symptoms and structural lung disease on chest computed tomography. Current guidelines recommend COPD diagnostic schemas that do not incorporate imaging abnormalities. OBJECTIVE: To determine whether a multidimensional COPD diagnostic schema that includes respiratory symptoms and computed tomographic imaging abnormalities identifies additional individuals with disease. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included 2 longitudinal cohorts: the Genetic Epidemiology of COPD (COPDGene), which enrolled 10 305 participants between November 9, 2007, and April 15, 2011, with longitudinal follow-up through August 31, 2022; and the Canadian Cohort Obstructive Lung Disease (CanCOLD), which enrolled 1561 participants between November 26, 2009, and July 15, 2015, with follow-up through December 31, 2023. EXPOSURE: Exposure included the new multidimensional COPD diagnostic schema, defined by (1) major diagnostic category: presence of the major criterion (airflow obstruction based on postbronchodilator forced expiratory volume in the first second of expiration [FEV1]/forced vital capacity ratio <0.70) and at least 1 of 5 minor criteria (emphysema or bronchial wall thickening on computed tomography, dyspnea, poor respiratory quality of life, and chronic bronchitis); or (2) minor diagnostic category: presence of least 3 of 5 minor criteria (which must include emphysema and bronchial wall thickening for individuals with respiratory symptoms potentially due to other causes). MAIN OUTCOMES AND MEASURES: All-cause mortality, respiratory cause-specific mortality, exacerbations, and annualized change in FEV1. RESULTS: Among 9416 adults in COPDGene (mean [SD] age at enrollment, 59.6 [9.0] years; 5035 [53.5%] were men; 3071 [32.6%] were Black; 6345 (67.4%) were White; 4943 [52.5%] currently smoked), 811 of 5250 individuals (15.4%) without airflow obstruction were newly classified as having COPD by minor diagnostic category, and 282 of 4166 individuals (6.8%) with airflow obstruction were classified as not having COPD. Reclassified individuals with a new COPD diagnosis had greater all-cause mortality (adjusted hazard ratio, 1.98; 95% CI, 1.67-2.35; P < .001) and respiratory-specific mortality (adjusted hazard ratio, 3.58; 95% CI, 1.56-8.20; P = .003), more exacerbations (adjusted incidence rate ratio, 2.09; 95% CI, 1.79-2.44; P < .001), and more rapid FEV1 decline (adjusted β = -7.7 mL/y; 95% CI, -13.2 to -2.3; P = .006) compared with individuals classified as not having COPD. Among individuals with airflow obstruction on spirometry, those no longer classified as having COPD based on this new diagnostic schema had outcomes similar to those without airflow obstruction. Among 1341 adults in CanCOLD, individuals newly classified as having COPD experienced more exacerbations (adjusted incidence rate ratio, 2.09; 95% CI, 1.25-3.51; P < .001). CONCLUSIONS AND RELEVANCE: A new COPD diagnostic schema integrating respiratory symptoms, respiratory quality of life, spirometry, and structural lung abnormalities on computed tomographic imaging newly classified some individuals as having COPD. These individuals had an increased risk of all-cause and respiratory-related death, frequent exacerbations, and rapid lung function decline compared with individuals classified as not having COPD. Some individuals with airflow obstruction without respiratory symptoms or evidence of structural lung disease were no longer classified as having COPD.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Bhatt SP, Abadi E, Anzueto A, et al. A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease. JAMA. 2025. PMID: 40382791. doi:10.1001/jama.2025.7358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。